Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis

Abstract

Objective Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Altered lymphocyte cell counts and a potential association with increased infection rates have been reported in RA patients treated with JAK inhibitors. This analysis was undertaken to evaluate the short‐, mid‐, and long‐term effects of tofacitinib on lymphocytes and infection rates in patients with RA. Methods In this post hoc analysis, absolute lymphocyte counts (ALCs) were obtained from phase III studies (12–24 months; n = 717–958) and phase I/II/III/long‐term extension studies of tofacitinib (≤117 months) (All RA population; n = 7,061); lymphocyte subset counts (LSCs) were from phase II studies (1.5–6 months’ exposure; n = 236–486), an ORAL Sequel vaccine substudy (~22 months; n = 198), and an ORAL Sequel lymphocyte substudy (~50 months; n = 55–1,035) of tofacitinib. The reversibility of ALC/LSC changes was evaluated. The relationship of ALC and LSC to infections was analyzed in the All RA population. The value of monitoring ALC alone was assessed by examining correlations between ALCs and LSCs. Results Tofacitinib treatment resulted in an initial increase in ALC versus pretreatment baseline, which gradually declined to steady state by ~48 months. CD4+ and CD8+ T cell counts decreased over long‐term treatment, and ALC and LSC changes were reversible upon treatment cessation. Patients with ALCs of <500 cells/mm3 had an increased risk of serious infections. There was no strong association between CD4+ T cell, CD8+ T cell, B cell, or natural killer cell counts and serious infection incidence rates. ALC and CD4+ or CD8+ T cell counts correlated well (R = 0.65–0.86). Conclusion Our findings indicate that monitoring of ALC alone appears to be adequate to assess infection risk in tofacitinib‐treated patients with RA.

Hemophagocytic syndrome associated with Mycobacterium bovis in a patient with X-SCID: a case report

“…Previous studies showed that tuberculosis infection caused by BCG vaccination usually occurs in immunodeficient children [7,8], especially for boys with low lymphocyte counts [9]. Due to the low lymphocyte counts, genetic analysis was performed, and the result of whole-exome sequencing confirmed the mutation in the IL2RG gene underlying X-SCID in the patient.…”

<p>Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives</p>

“…A pooled analysis of tofacitinib in patients with rheumatoid arthritis reported that patients with an ALC less than 500 cells/mm 3 had an increased risk of infection and identified trends towards an increased rate of herpes zoster and opportunistic infections with lower ALC values. 54 Dosing should be discontinued in patients with an ALC and ANC of less than 500 cells/mm 3 . Treatment should be interrupted in patients with a hemoglobin of less than 8 g/dL or a decrease of more than 2 g/dL.…”

Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing

“…Closeness centrality analysis assigned a high rank to Tofacitinib and Ruxolitinib, which are currently being assessed in clinical trials. Tofacitinib and Ruxolitinib exert immunomodulatory effects as Janus kinase inhibitors 20,21 . Thus, administration with these drugs may mitigate immune-mediated lung injury and reduce functional deterioration caused by an overamplified host inflammatory response.…”